La Seda De Barcelona Hopes To Halt Insolvency With Debt Deal

Spanish Spanish PET producer La Seda de Barcelona will ask shareholders to approve its debt refinancing plan and allow it to withdraw from insolvency proceedings on Wednesday, a person close to the company with knowledge of the plan told Reuters.

La Seda said in a stock market notice on Tuesday that it had reached a preliminary deal to refinance 75% of its syndicated debt with creditors, after saying last week it would file for insolvency.

The company should now be able to restructure €235 million ($307 million) of syndicated debt following the agreement, with over half its creditors signing up to refinance 75.4% of the debt.

"That means all the legally required thresholds to implement the company's syndicated debt refinancing proposal have been reached," La Seda de Barcelona said in a statement. "If the process to withdraw from insolvency proceedings is approved tomorrow, (biggest creditor) Anchorage's plan to convert the debt into capital will go ahead, but that has to be decided at tomorrow's meeting," the person said.

The Catalonia-based company, which makes bottles in Europe, Turkey and North Africa, has been in talks with creditors since last September after high material costs and excess supply of the PET plastic containers it makes put pressure on the business.

The firm, whose biggest creditor is U.S. hedge fund Anchorage, said last week it would start insolvency proceedings after failing to get the 75% of creditors it needed on board with its refinancing plan.

La Seda had €600 million of debt at the end of 2012, according to company filings, and has €462 million in syndicated loans from banks, according to Reuters loan market news and analysis service RLPC.

A source close to the talks had said last week that €235 million of that syndicated debt needed to be restructured.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.